The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable ...

has expanded its reach by acquiring a 50% equity interest in MSO Metro, LLC, enhancing their management of 50 outpatient physical therapy clinics, mainly in New York. This strategic acquisition ...

The acquisition aligns with Merck’s strategic focus on advancing oncology treatment options and addressing some of the most challenging tumor types through innovative therapies. Notably, Modifi ...

Whitney Ijem’s rating is based on a strategic ... s expertise in gene therapy, particularly concerning BBS-related conditions, which could enhance Rhythm’s existing treatment options.

New strategic partnership leverages the power of the Dyno platform ... and commercialization activities for multiple neurological gene therapy product candidates leveraging novel Dyno capsids. Roche ...

The move reflects the continuing influence and strategic decisions of the Ziff family within the company. For further insights into GB:TOWN stock, check out TipRanks’ Stock Analysis page.

As a platform built to solve the most critical challenges facing gene therapy developers, Dyno’s industry-leading gene delivery solutions enable Dyno partners to create ever better gene therapies.

Then, they can use them with the features of Invisalign Smile Architect to develop a personalized treatment plan. The new software from Align integrates with its digital platform, a combination of ...

Comprehensive policies that incorporate demography, family planning, and reproductive health can promote higher levels of stability and development, thereby improving the health and livelihood of ...